search
Back to results

Fluids in Sepsis and Septic Shock (FISSH)

Primary Purpose

Sepsis, Septic Shock

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
higher chloride crystalloid
higher chloride albumin
lower chloride crystalloid
lower chloride albumin
Sponsored by
McMaster University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient must be at least 16 years of age
  2. Within 6 hours from presentation to hospital or activation of MET/RACE team to ward
  3. Requires fluid resuscitation for refractory hypotension OR organ hypoperfusion

    • refractory hypotension definition - sBP <90 OR MAP <65 after 1L bolus given over 1 hour or less
    • organ hypoperfusion - lactate >4
  4. Suspected source of infection as etiology for hypotension
  5. Treating physician anticipates patient will require admission to ICU

Exclusion Criteria:

  1. Intracranial bleed or intracranial hypertension during this hospital admission
  2. Acute burn injury (>10% body surface area)
  3. Bleeding/hemorrhage as likely cause of hypotension
  4. Plan in place to change goals of care to palliation
  5. Previously enrolled in FISSH
  6. Previously enrolled in confounding trial
  7. Transfer from another hospital or facility
  8. Admission directly from the operating room or PACU

Sites / Locations

  • Juravinski Hospital-Hamilton Health Sciences
  • Centre Hospitalier Universitaire de Sherbrooke

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

higher chloride solutions

lower chloride solutions

Arm Description

higher chloride crystalloid (Normal saline) higher chloride albumin (5% Octalbin)

lower chloride crystalloid (Ringer's lactate) lower chloride albumin (5% Plasbumin)

Outcomes

Primary Outcome Measures

Consent Rate
Consent rate will be considered adequate if greater than 70% of substitute decision makers (SDMs) or patients when approached for consent choose to participate.
Patient Recruitment
Successful recruitment will be defined as achieving enrolment of 50 patients over the 12-month study period. This works out to approximately 1 patient/center/month. Once the pilot trial begins, the screening logs will be reviewed at all three study centers by the study steering committee on a monthly basis. We will record exclusions and reasons for physician refusals.
Protocol Adherence
Successful adherence will be defined as patients receiving at least 75% study fluid of all intravenous fluid that is administered in the ICU excluding blood products and medication infusions.

Secondary Outcome Measures

Hospital length of stay
Hospital mortality
Mortality during index hospitalization censored at 90 days.
Renal replacement therapy use
Any use of renal replacement therapy including hemodialysis, peritoneal dialysis or continuous renal replacement. This will be reported as a dichotomous outcome.
ICU length of stay
Hyperkalemia
Number of participants with any serum potassium value >5mmol/L.
Acidosis
Number of participants with any serum pH <7.20

Full Information

First Posted
April 8, 2016
Last Updated
August 27, 2018
Sponsor
McMaster University
Collaborators
Hamilton Health Sciences Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT02748382
Brief Title
Fluids in Sepsis and Septic Shock
Acronym
FISSH
Official Title
Fluids in Sepsis and Septic Shock: A Pilot Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
August 18, 2016 (Actual)
Primary Completion Date
August 19, 2017 (Actual)
Study Completion Date
August 19, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
McMaster University
Collaborators
Hamilton Health Sciences Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Despite evidence of the physiologic benefits and possible lower mortality associated with low chloride solutions, normal saline remains the most wildly used fluid in the world. Given uncertainty about the impact of lower chloride versus higher chloride solutions on mortality, it is unlikely that clinical practice will change without new and direct RCT evidence. Editorials published in leading critical care journals have called for RCT's to address this important clinical question. The proposed feasibility RCT will investigate the feasibility of a large-scale trial directly comparing low chloride versus normal chloride for resuscitation in septic shock on patient-important outcomes such as mortality and AKI.
Detailed Description
Severe infection can lead to many complications within the human body including low blood pressure, which is called septic shock. The main treatments for septic shock are intravenous antibiotics and intravenous fluid. There are many different intravenous fluids available for doctors to use. Each one of these fluids has potential advantages as well as potential disadvantages. Doctors will often look at many things when deciding which fluid to give including the results of bloodwork and the clinical characteristics of the patients themselves. There is limited direction from research studies taht using one fluid type is better than another. Some preliminary research in the field has suggested that one specific electrolyte, call chloride, may be harmful when given to patients in high concentrations. Animal research has shown that the administration of high chloride fluids may be harmful to the lungs, kidneys, gastrointestinal and muscle cells. Some intravenous fluids have higher concentrations of chloride than others. The investigators plan to study the impact of giving patients with severe infection intravenous fluids with either a high chloride concentration (normal saline or high chloride albumin) or a low chloride concentration (Ringers Lactate or low chloride albumin). Although, the investigators plan for a larger trial looking at patient-important outcomes such as rate of death, kidney failure and length of stay in the ICU the investigators think it's important to start with a feasibility study. If the investigators are able to show a larger trial is feasible then the investigators will apply for further funding and use the lessons learned from this pilot to optimize the larger study. The larger study has the potential to guide the care of critically ill patients with infection worldwide.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Septic Shock

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
higher chloride solutions
Arm Type
Active Comparator
Arm Description
higher chloride crystalloid (Normal saline) higher chloride albumin (5% Octalbin)
Arm Title
lower chloride solutions
Arm Type
Active Comparator
Arm Description
lower chloride crystalloid (Ringer's lactate) lower chloride albumin (5% Plasbumin)
Intervention Type
Other
Intervention Name(s)
higher chloride crystalloid
Intervention Description
Normal saline
Intervention Type
Other
Intervention Name(s)
higher chloride albumin
Intervention Description
5% Octalbin
Intervention Type
Other
Intervention Name(s)
lower chloride crystalloid
Intervention Description
Ringers Lactate
Intervention Type
Other
Intervention Name(s)
lower chloride albumin
Intervention Description
5% Plasbumin
Primary Outcome Measure Information:
Title
Consent Rate
Description
Consent rate will be considered adequate if greater than 70% of substitute decision makers (SDMs) or patients when approached for consent choose to participate.
Time Frame
12 months
Title
Patient Recruitment
Description
Successful recruitment will be defined as achieving enrolment of 50 patients over the 12-month study period. This works out to approximately 1 patient/center/month. Once the pilot trial begins, the screening logs will be reviewed at all three study centers by the study steering committee on a monthly basis. We will record exclusions and reasons for physician refusals.
Time Frame
12 months
Title
Protocol Adherence
Description
Successful adherence will be defined as patients receiving at least 75% study fluid of all intravenous fluid that is administered in the ICU excluding blood products and medication infusions.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Hospital length of stay
Time Frame
Duration of index hospital stay censored at 90 days.
Title
Hospital mortality
Description
Mortality during index hospitalization censored at 90 days.
Time Frame
hospital stay or up to 90 days
Title
Renal replacement therapy use
Description
Any use of renal replacement therapy including hemodialysis, peritoneal dialysis or continuous renal replacement. This will be reported as a dichotomous outcome.
Time Frame
RRT use during index hospital stay censored at 90 days.
Title
ICU length of stay
Time Frame
Duration of index ICU stay censored at 90 days.
Title
Hyperkalemia
Description
Number of participants with any serum potassium value >5mmol/L.
Time Frame
Incidence during index ICU stay or up to 30 days
Title
Acidosis
Description
Number of participants with any serum pH <7.20
Time Frame
Incidence during index ICU stay or up to 30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient must be at least 16 years of age Within 6 hours from presentation to hospital or activation of MET/RACE team to ward Requires fluid resuscitation for refractory hypotension OR organ hypoperfusion refractory hypotension definition - sBP <90 OR MAP <65 after 1L bolus given over 1 hour or less organ hypoperfusion - lactate >4 Suspected source of infection as etiology for hypotension Treating physician anticipates patient will require admission to ICU Exclusion Criteria: Intracranial bleed or intracranial hypertension during this hospital admission Acute burn injury (>10% body surface area) Bleeding/hemorrhage as likely cause of hypotension Plan in place to change goals of care to palliation Previously enrolled in FISSH Previously enrolled in confounding trial Transfer from another hospital or facility Admission directly from the operating room or PACU
Facility Information:
Facility Name
Juravinski Hospital-Hamilton Health Sciences
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8V 1C1
Country
Canada
Facility Name
Centre Hospitalier Universitaire de Sherbrooke
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 3H5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28729329
Citation
Rochwerg B, Millen T, Austin P, Zeller M, D'Aragon F, Jaeschke R, Masse MH, Mehta S, Lamontagne F, Meade M, Guyatt G, Cook DJ; Canadian Critical Care Trials Group. Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial. BMJ Open. 2017 Jul 20;7(7):e017602. doi: 10.1136/bmjopen-2017-017602.
Results Reference
derived

Learn more about this trial

Fluids in Sepsis and Septic Shock

We'll reach out to this number within 24 hrs